-
Oral small molecule PD-L1 inhibitor!
Time of Update: 2021-12-26
Source: Guanlan PharmaceuticalRecently, Arnold Pharma announced that its original innovative drug, the oral PD-L1 inhibitor AN4005, has been approved by the National Medical Products Administration (NMPA) for drug clinical trials.
-
Domestic anti-tumor drugs ushered in a big outbreak, local pharmaceutical companies are vying to exert their strength
Time of Update: 2021-12-26
It is understood that, in addition to Shandong New Times Pharmaceuticals recently submitted and accepted application for the 4 types of generic marketing of azacitidine for injection, many innovative anti-tumor drugs have also been approved for clinical use.
-
China Biopharmaceuticals' self-developed class 1 new drug P2X3 receptor antagonist received clinical approval for the first time
Time of Update: 2021-12-26
Text: SunshineOn December 16, the official website of CDE showed that the clinical trial application of TCR1672, a subsidiary of China Biopharmaceuticals, was approved for the treatment of refractory chronic cough .
-
Jiangxi Food and Drug Administration releases good news: products of innovative review channels are available for review
Time of Update: 2021-12-26
At the same time, a number of measures also support the development of Nanchang biomedical industry clusters, mentioning that it will strengthen the guidance and assistance to the Chinese Medicine Science and Technology City, Jinxian Industrial Park, and the Xiaolan Industrial Park; promote the implementation of the industrial planning and construction of the "Chinese Medicine Science and Technology City" Work to cultivate the traditional Chinese medicine industry cluster in the "Technological Innovation City of Traditional Chinese Medicine" .
-
A batch of pharmaceutical companies declared bankruptcy
Time of Update: 2021-12-26
Guizhou Sanli Pharmaceutical plans to pay a deposit of RMB 50 million to participate in the public recruitment of investors for the bankruptcy and reorganization of Guiyang Dechangxiang Pharmaceutical .
-
BTK inhibitors have been successful Can Syk work miracles?
Time of Update: 2021-12-26
1 Domestic clinical filing of HMPL-523(Image source: http:// Summary06 SummaryIn summary, it is a small microcosm of the development of Syk targets and their inhibitors .
-
The domestic drug price system is gradually clear, and the internationalization of innovative drugs will enter a critical period
Time of Update: 2021-12-26
It is worth noting that with the steady advancement of medical reform and the continuous expansion of centralized procurement, the innovation and transformation of domestic pharmaceutical companies have also begun to accelerate .
-
Innovative pharmaceutical companies IPOs frequently "break", how to realize the commercial value?
Time of Update: 2021-12-26
6 billion; Cinda's anticancer drug tislelizumab globally Commercializing together with Novartis, the two parties also reached an authorized cooperation transaction with a down payment of US$650 million and a total of US$2.
-
Under the high market boom, the performance and R&D investment of local pharmaceutical companies will continue to grow
Time of Update: 2021-12-26
71 billion yuan, and the company's revenue in the first three quarters of this year has reached 2.
In the future, pharmaceutical machinery companies will continue to develop new technologies and products, innovate, improve and upgrade existing equipment according to industry and customer needs .
-
"Spoiler" in the pharmaceutical industry planning in 2022: Chutian expects that next year’s performance growth target will not be less than 20%
Time of Update: 2021-12-26
There are three directions in the market, including vigorously promoting the replacement of high-end pharmaceutical equipment; and vigorously expanding overseas business .
In general, domestic pharmaceutical machinery companies such as Chutian and Tofflon are currently increasing their international layout by recruiting talents and forming teams.
-
After the dispute, Bojian did not give up the Alzheimer's disease drug Aduhelm. The confirmatory clinical trial will be launched in May of the following year.
Time of Update: 2021-12-26
In early November, an elderly patient died after receiving treatment with Biogen's Alzheimer's disease drug Aduhelm;In November, Bojian received a "negative trend vote" from the European Medicines Agency's Committee on Pharmaceuticals for Human Use (CHMP) on Aduhelm's application, and CHMP rejected Aduhelm's listing in Europe .
-
5980 yuan/bottle!
Time of Update: 2021-12-26
The data showed that Envolimab as a single agent (administered by 150mg QW subcutaneously) was used in 103 cases of MSI-H/dMMR The objective response rate (ORR) of solid tumor patients with second-line and above treatment was 44.
-
Eli Lilly's new generation of BTK inhibitor LOXO-305 submits rolling application for marketing to FDA
Time of Update: 2021-12-26
On December 15th, Eli Lilly announced that it has submitted a rolling application (NDA) for the next-generation BTK inhibitor pirtobrutinib (LOXO-305) to the FDA for the treatment of mantle cell lymphoma .
-
The first domestic product!
Time of Update: 2021-12-25
Vibotuzumab mechanism of actionVibotuzumab was first approved by the FDA in June 2019 (trade name: Polivy), combined with bendamustine + Rituxan (rituximab) for the treatment of relapse or refractory that has received at least two previous treatments Adult patients with curative (R/R) diffuse large B-cell lymphoma (DLBCL) .
-
Over 500 million yuan in the new generation of anticoagulant drug market, ushering in new entrants
Time of Update: 2021-12-25
In the future, as the number of relevant filing companies increases, Fondaparinux Competition in the sodium injection market will gradually intensify .
At present, in addition to Sihuan Pharmaceutical, four companies that have passed the consistency evaluation of Fondaparinux Sodium Injection include Hengrui Pharmaceutical, Nanjing Jianyou, Zhaoke Pharmaceutical, and Yangzijiang Pharmaceutical.
-
Driven by centralized procurement, price reduction of anti-tumor drugs has become a trend
Time of Update: 2021-12-25
Out of optimism about the market prospects, in China, many pharmaceutical companies have been actively deploying CAR-T cell therapy drugs in recent years .
Under the background that domestic pharmaceutical companies are actively deploying CAR-T cell therapy drugs in the field, two domestic products have been approved for listing in China.
-
The retail of Chinese patent medicines for cardiovascular and cerebrovascular diseases will break through 12 billion, and multi-brands will rise by more than 30%
Time of Update: 2021-12-25
For example, according to related data, in 2021, it is expected that the sales of the Chinese city's physical pharmacy terminal cardio-cerebrovascular patent medicine market will exceed 12 billion yuan .
-
After a lapse of 14 years, the country's first drug use regulations ushered in a major overhaul!
Time of Update: 2021-12-25
The new version of the "Regulations on the Use of Medicines in Shandong Province" has seven chapters and 43 articles, which are divided into general provisions, drug purchase and storage, drug deployment and application, pharmacovigilance, supervision and management, legal responsibilities, and supplementary provisions.
-
From January 20 next year, over 40 selected drugs in centralized procurement will be renewed
Time of Update: 2021-12-25
According to the information form for renewal of selected drugs in the national centralized procurement part of the notice, it includes levocetirizine hydrochloride tablets from Hunan Jiudian Pharmaceutical Co.
-
More than 40 kinds of drugs for rare diseases have been included in the medical insurance, continuously reducing the burden on patients
Time of Update: 2021-12-25
In addition, human coagulation factor IX for the treatment of hemophilia, clofenac soft capsules for the treatment of adult wild-type or genetic transthyretin amyloid cardiomyopathy, and injection of a new long-acting lipid-lowering drug iloyuumab Liquid has also successfully entered the adjusted medical insurance drug list, which will bring the gospel of cost reduction for patients with related rare diseases and improve the quality of life .
